REG - SkinBioTherapeutics - Notice of Investor Meet Company Presentation

SkinbiotherapeuticsAnnouncement

04/10/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD0460Ha&default-theme=true

RNS Number : 0460H  SkinBioTherapeutics PLC  04 October 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Notice of Investor Meet Company presentation

4 October 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, will be giving an update to investors on Friday 11
October 2024 via the Investor Meet Company platform.

The presentation will take place at 10am (BST) via this link HERE
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc) .
Questions can be submitted pre-event via the Investor Meet Company
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc)
 dashboard up to the day before the meeting or at any time during the
presentation.

Investors who already follow SkinBioTherapeutics on the Investor Meet
Company platform will automatically be invited. Investors can sign up
to Investor Meet Company for free via this link
(http://www.investormeetcompany.com/companies/skinbiotherapeutics-plc) .

 

For more information please contact:

 

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSUFELELSEIS